Drug Database
PR

pregabalin (pregabalin, YuHan / YHD 1119 / YHD1119)

✓ Approved

YuHan · CACNA2D1 · Small Molecule

What is pregabalin?

pregabalin is a small molecule developed by YuHan. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand Namespregabalin, YuHan, YHD 1119, YHD1119
CompanyYuHan
Drug ClassSmall Molecule
Molecular TargetCACNA2D1
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, YuHan

Mechanism of Action

Molecular Targets

pregabalin acts on 1 molecular target:

CACNA2D1calcium voltage-gated channel auxiliary subunit alpha2delta 1 (LINC01112, CACNA2)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

pregabalin is developed for 2 unique indications across 1 therapeutic area.

Therapeutic AreaConditionPhase
Nervous system disordersDiabetic neuropathy✓ Approved
Nervous system disordersPost herpetic neuralgia✓ Approved

Related Research Articles

PubMedPain medicine case reports2026-07-15

Differentiating Etiologies of Pain in the Presence of Dorsal Arachnoid Web: A Case Report.

Gill Maher M, Wang Eric E, Dai Sally S, Wang Jerry J et al.

Dorsal arachnoid web (DAW) is a rare spinal pathology involving a thickened band of arachnoid tissue that compresses the thoracic spinal cord, potentially causing myelopathy. Patients with DAW who present with pain or neurological complaints should be evaluated thoroughly to determine the most likely cause of symptoms, particularly in the context of clinical presentations that overlap with other neurological or pain syndromes. A 76-year-old man with a history of inclusion body myositis and prior middle cerebral artery stroke presented with left-sided pain and weakness. Although DAW was noted on imaging, further evaluation indicated that the patient's pain symptoms were due to central pain syndrome secondary to his previous stroke, given the correlation between symptom localization and stroke territory. He was managed successfully with pregabalin and amitriptyline without the need for surgical intervention. In patients with overlapping neurological and pain syndromes, accurate diagnosis is essential to determining the best choice of treatment.

PMID 42456069
Read full article →
PubMedJournal of intellectual disability research : JIDR2026-07-15

Prevalence of Psychotropic Use and Psychotropic Polypharmacy in a Finnish National Cohort of Persons With Intellectual Disabilities.

Virtanen Ville V, Saastamoinen Leena L, Arvio Maria M, Vesala Hannu T HT et al.

Psychotropic use and psychotropic polypharmacy are common in people with intellectual disabilities, but representative population-based studies on this topic are scarce. We evaluated the prevalence of psychotropic use and psychotropic polypharmacy in a Finnish nationwide cohort of people with intellectual disabilities aged 0-97 years. The annual prevalence of psychotropic use in 2019 was studied among 37 196 individuals with intellectual disabilities and an age- and sex-matched comparison cohort with no diagnosis of intellectual disabilities. Psychotropics included antipsychotics, antidepressants, anxiolytics, hypnotics and sedatives and antiepileptics indicated for bipolar disorder (carbamazepine, valproic acid, lamotrigine, pregabalin and clonazepam). Prevalence of interclass psychotropic polypharmacy (use from ≥ 2 different psychotropic groups) was evaluated in a 4-month time window at the end of 2019. Prevalence of psychotropic use was higher in the intellectual disability cohort (42.3%) than comparison cohort (15.0%). Antipsychotics were the most common psychotropic group in the intellectual disability cohort (28%), with lower prevalence in the comparison cohort (3.3%). The prevalence of antidepressant use was 19.4% in the intellectual disability cohort and 9.7% in the comparison cohort. A likely indication was identified for 52.9% of psychotropic users with intellectual disability (major psychiatric comorbidity 38.1%, challenging behaviour 22.1%). Psychotropic polypharmacy was more common in the intellectual disability cohort (18.2%), than in the comparison cohort (3.6%). Our findings highlight concerns about psychotropic polypharmacy and potential overmedication. Using a comprehensive, nationwide cohort, this study emphasises the need for more evidence-based, person-centred approaches, including careful diagnostics, non-pharmacological interventions and regular treatment reviews.

PMID 42454604
Read full article →
PubMedDiagnostics (Basel, Switzerland)2026-07-15

Neuropathic Corneal Pain and Blepharospasm: A Case Series.

Thia Zhang Zhe ZZ, Takahashi Aya A, Yu Mingyi M, Liu Chang C et al.

Background and Clinical Significanc: Neuropathic corneal pain is a debilitating condition characterized by ocular pain disproportionate to clinical signs, often resulting from peripheral and central sensitization of the corneal somatosensory pathway. Emerging evidence suggests that chronic involuntary muscle contraction in blepharospasm may lead to irritation of trigeminal afferents and corneal neurogenic inflammation, potentially predisposing patients to neuropathic corneal pain. Given its debilitating nature, early recognition can prevent the progression of neuropathic sequelae. This study examines the potential role of blepharospasm as a predisposing factor contributing to neuropathic corneal pain. Case Presentation: This retrospective case series describes three cases (median age: 50 years) of neuropathic corneal pain in association with blepharospasm and their clinical course following multimodal treatment over a median follow-up period of one year. Ocular surface was evaluated using slit-lamp biomicroscopy, while corneal nerve structure and morphology were assessed with in vivo confocal microscopy. All the three subjects presented with minimal ocular surface staining but disproportionate ocular pain characterized by burning sensation and photophobia. Proparacaine challenge testing was performed to determine the subtype of neuropathic corneal pain. Pain symptoms and quality of life were evaluated using the Ocular Pain Assessment Survey and Ocular Surface Disease Index questionnaires. In vivo confocal microscopy demonstrated characteristic corneal nerve abnormalities including reduced corneal nerve density, increased nerve tortuosity, and the presence of microneuromas. Treatment included oral Pregabalin or Gabapentin, topical lubricants, Cyclosporine 0.05% (1 case), and 20% autologous serum eye drops (1 case). Two of the three cases received four to five injections of botulinum toxin for blepharospasm, whereas one had undergone a single injection prior to review. All patients also received weekly periorbital quantum molecular resonance electrotherapy for two months. Improvements were observed across multiple domains of the Ocular Pain Assessment Survey and Ocular Surface Disease Index evaluation, including ocular pain, photophobia, non-ocular pain, and quality-of-life measures following multimodal treatment. The co-existence of blepharospasm and neuropathic corneal pain observed in our cases supports a possible association between chronic periocular muscle hyperactivity and corneal nociceptor sensitization. Proposed mechanisms include chronic trigeminal nerve irritation, neurogenic inflammation, and sensitization mediated by pro-inflammatory neuropeptides. Multimodal treatment targeting both motor hyperactivity and neuropathic pain pathways appeared to provide symptomatic relief, including the use of quantum molecular resonance electrotherapy, which might modulate pain pathways, block nociceptor neurotransmission, and accelerate corneal nerve regeneration. Given the complexity of the neural pathways responsible for ocular discomfort, further studies are required to elucidate the relationship between neuropathic corneal pain and blepharospasm in larger cohorts, as well as refine existing therapeutic approaches, including evaluating the therapeutic role of electrotherapy. Conclusions: Blepharospasm may represent a potential predisposing factor of neuropathic corneal pain. Early recognition and concurrent treatment of blepharospasm and neuropathic corneal pain can effectively relieve symptoms and improve quality of life. Adopting a multimodal treatment approach is therefore recommended.

PMID 42449756
Read full article →
PubMedFrontiers in physiology2026-07-13

Pharmacological and non-pharmacological therapies for chronic pancreatitis pain: a narrative review.

Alsaleh Tareq T, Arain Mustafa M, George John J

Chronic pancreatitis (CP) pain is the major driver of morbidity, reduced quality of life, healthcare use, and opioid exposure in affected patients. Pain in CP is heterogeneous and often correlates poorly with structural pancreatic abnormalities alone. It may arise from overlapping obstructive, neuropathic, nociplastic, and psychosocial mechanisms, making simple stepwise analgesic escalation insufficient for many patients. The emerging evidence supports a multidimensional strategy for treating CP pain. In some patients, pain is driven mainly by ductal obstruction, stones, strictures, inflammatory head masses, or other structural complications that may respond to endoscopic or surgical decompression. On the other hand, pain may persist because of pancreatic neuroplasticity, peripheral nerve injury, central sensitization, widespread hyperalgesia, and psychological distress. Newer tools such as the Comprehensive Pain Assessment Tool Short Form, electronic body mapping, and pancreatic quantitative sensory testing may help identify clinically relevant pain phenotypes beyond imaging alone. Although pharmacologic options remain limited, medications can provide relief in appropriately selected patients. Pregabalin has the strongest direct evidence among neuromodulators with favorable results. However, opioids remain widely prescribed even though they worsen dependency, opioid-induced hyperalgesia, and treatment resistance when used without reassessment of the dominant pain mechanism. Nonpharmacological modalities are an essential component. These include alcohol and smoking cessation, nutritional and endocrine optimization, and cognitive behavioral therapy. Endoscopic and surgical therapies are most effective when pain is anatomy-driven, while neuromodulation and other emerging interventions remain investigational but may be a promising option for nociplastic pain. Pain in CP should be approached as a dynamic biopsychosocial process by a multidisciplinary team. In addition to pain intensity, outcome measures should capture pain interference, function, quality of life, and opioid burden. Correctly identifying the pain phenotype and matching patients with the appropriate mechanism-based therapies and structural interventions will maximize treatment success and reduce prolonged opioid escalation and repeated low-yield interventions.

PMID 42440464
Read full article →
PubMedCase reports in anesthesiology2026-07-12

Perioperative Pregabalin for Recurrent Intractable Hiccups: A Case Report and Literature Review.

Lei David D, Yamaguchi Craig T L CTL, Moody Alastair E AE, Swenson Jeffrey D JD

Involuntary diaphragmatic spasms, "hiccups," commonly resolve spontaneously over a few minutes but can occasionally persist, presenting a challenging perioperative problem. Pregabalin is a frequently utilized gabapentinoid in the treatment of neuropathic pain, but its effectiveness for treating hiccups during the perioperative period has not been well established. We present a patient with a 7-year history of intractable hiccups resistant to chlorpromazine, baclofen, gabapentin, and cervical epidural injections presenting for orthopedic surgery. Perioperative and postoperative pregabalin administration significantly reduced the frequency and severity of hiccups. This case demonstrates the potential for pregabalin in the management of refractory hiccups.

PMID 42436812
Read full article →
PubMedClinical case reports2026-07-12

Management of Pain and Pruritus in Pediatric Recessive Dystrophic Epidermolysis Bullosa.

Marttinen Maiju K MK, Sipilä Reetta R, Vuorimaa Hanna H, Ståhl Minna M et al.

The current report presents a tailored and efficient pain management strategy for a 7-year old boy with recessive dystrophic epidermolysis bullosa severe generalized. Successful management of pain associated with demanding wound care was achieved through a combination of oral pregabalin, topical gabapentin-lidocaine, and psychological interventions.

PMID 42437100
Read full article →

+5281 more articles available with a free account

Sign up free to view all articles →

Ask about pregabalin